Introduction
Epilepsy is one of the most common neurological diseases worldwide [1] . The disease has an impact on the reproductive system. Males with epilepsy have lower fertility rates, hyposexuality and reduced potency in the population [2, 3] . Establishing a direct connection between reduced fertility and epilepsy has been difficult [4] [5] [6] . Although reduced potency and sperm abnormalities were reported in some studies, the etiology is thought to be multifactorial [10] [11] [12] . Thus, the effects of antiepileptic drugs on sex hormones and the reproductive system are under investigation [5, [7] [8] [9] [10] 13] .
Different results have been obtained from studies that were conducted on the p450 enzyme-inducing and non-enzyme-inducing anti-epileptic drugs [10, [13] [14] [15] [16] [17] [18] . The vast majority of the studies have focused on classic anti-epileptic drugs, whereas there are insufficient data regarding the effects of levetiracetam (LEV), a second-generation anti-epileptic, on fertility. LEV is known for its low incidences of both adverse effects and drug-drug interactions [19] . Animal studies concerning the effects of LEV on sex hormones concluded that LEV might affect steroid hormone secretion [20, 21] . However, human studies yielded diverse results [22, 23] .
In our study, we have investigated the effects of LEV on sex hormones and sperm parameters by acquiring pre-and postmedication data in newly diagnosed epilepsy patients who were treated with LEV monotherapy. We have also sought the association between sperm parameters and treatment characteristics, such as maximum dose, daily dose and treatment duration.
Materials and methods
This study was approved by our institutional ethics committee (Regional Education and Research Hospital, Erzurum, file number: 2014/22-3), and written informed consent was obtained from all subjects.
Participants
Between March 2014 and March 2015, all patients who had a new diagnosis of partial or generalized epilepsy were considered for our study. From this population, 30 male patients were selected according to the following inclusion criteria: age between 15 and 45 years; having normal neuroimaging findings; not having a diagnosis of hypo/hyperthyroidism, acute or chronic forms of cardiopulmonary, hepatobiliary and renal diseases; not using any form of hormone replacement therapy; not having any type of drug or substance addiction/abuse; no history of testicular surgery, deformity-atrophy, varicocele and urogenital disease including STDs; and no history or diagnosis of psychiatric illness.
Following recruitment, testicular Doppler ultrasonography was performed for all patients to exclude the diagnosis of undetected varicocele, testicular atrophy-deformity, cryptorchidism and infectious diseases, such as epididymitis or orchitis.
From this patient population, one patient was excluded from the study due to the addition of an anti-depressant drug to the existing treatment regime, and three patients were excluded due to continuation of seizures with LEV monotherapy. Combined therapy was introduced to these patients. The study data were gathered from 26 patients.
Treatment and data acquisition
LEV treatment started with introducing 500 mg/day and gradually increased to 1000 mg/day over two weeks. All patients were to revisit the clinician after a month, except those who had seizures during first month were checked immediately.
Pre-and post-treatment blood tests and semen analyses were performed for all patients. The post-treatment checkpoint was determined if a period of eight weeks had passed since the last seizure for each patient. If there was no event, the earliest data was acquired at the end of the 8th week; if there was an event, the patient was followed up throughout the eight weeks of the seizurefree period. Treatment duration was defined as the elapsed time between the pre-and post-treatment checkpoint. The daily dose was calculated by dividing the total dose by the treatment duration (days). The maximum dose was defined as the highest dose used within the treatment duration. Fasting venous blood samples were collected in the morning and repeated at the exact same time after treatment. The sex hormone profile consisted of luteinizing hormone (LH, normal range: 3.1-34.6 mIU/mL), follicle-stimulating hormone (FSH, normal range: 1.4-18.1 mIU/mL), prolactin (PRL, normal range: 2.1-17.7 ng/mL), testosterone (T, normal range: 6.13-27.34 nmol/L), and estradiol (E2, normal range: 11.6-41.2 pg/mL).
All semen samples were obtained through masturbation after 3-6 days of abstinence. After liquefaction, the samples were evaluated for sperm concentration, motility, and morphology using the SQA-V automated sperm quality analyzer (Spermalite/ SQA-V; Medical Electronic Systems Ltd, Caesarea Industrial Park, Israel).
Statistical analysis
Summary statistics of the study groups are presented as the mean and the 95% CI for mean. Distribution of normality was assessed with the D'Agostino-Pearson test. Continuous variables with normal distribution belonging to the different epilepsy types were compared using the Student t test. Pre-and post-treatment comparison between individuals was performed with a paired t test. Statistical relationships between variables were assessed with the Pearson correlations coefficient. A two-tailed p-value <0.05 was considered statistically significant. All statistical analyses were performed using MedCalc statistics software (MedCalc, version 12.2.1.0, Mariakerke, Belgium).
Results
The study population consisted of 26 male subjects newly diagnosed with epilepsy. Their mean age was 28.6 AE 8.1 years (range, 18-43 years). The subjects were divided into two groups according to the type of seizures they had. Eight of 26 subjects had partial seizures (30.7%), whereas 18 subjects suffered from generalized seizures (69.3%). In the overall study population, the mean maximum dose, daily dose and treatment duration (at the point when the final sperm test was performed) were 1278.8 AE 334.1 mg, 1046.4 AE 141.6 mg and 13.7 AE 2.3 weeks, respectively. Dosages and treatment durations according to the different seizure types are summarized in Table 1 . There were no significant differences between groups regarding the maximum dose, treatment duration and daily dose.
Two sets of data regarding sperm motility, functionality and count were obtained from all subjects. Serum LH, FSH, PRL, T and E2 levels were also obtained along with sperm count. Data from the sperm analysis and blood samples obtained before and during the levetiracetam treatment from both groups and the overall study population with corresponding p-values are presented in Tables 2  and 3 . The final total sperm count, percentage of normal morphology and functional sperm count were significantly lower in both groups compared with the pre-treatment values. In addition to these parameters, the percentage of sperm motility was higher in the pre-treatment overall study population than in the post-treatment.
Correlation was sought between sperm parameters and features of the levetiracetam medication. There was moderate (Fig. 1 ).
Discussion
Our results showed that LEV treatment did not alter the sex hormone levels in patients with partial and generalized epilepsy. On the other hand, monotherapy negatively affected the sperm count, sperm morphology, motility and sperm functionality.
Furthermore, a decrease in number of functional sperm was associated with an increased daily dose of LEV.
The reproductive system can be affected by epilepsy, and pituitary hormone abnormalities can be encountered in patients with epilepsy. The mechanism underlying this effect has a close relationship with the alteration of signals in the hypothalamicpituitary axis. The pituitary gland is responsible for releasing sex hormones, including FSH and LH, whereas the hypothalamus indirectly controls these hormones by releasing the gonadotropinreleasing hormone that targets receptors in the pituitary gland [24] . During epileptic discharge, the hypothalamus receives altered signals from the cerebral cortex, amygdala and hippocampus. GABA and glutamate contribute to this altered signaling process as mediators [24] . Some AEDs associated with the p450 enzyme system in the liver also affect the sex hormone levels [25] . The effects of carbamazepine (CBZ) have been attributed to an elevation of the sex hormone binding globulin, rather than the metabolism or production of sex hormones [10, 13, 26] . Studies concerning the effects of valproic acid (VPA) have yielded more diverse results. Several studies have showed no association between VPA treatment and sex hormones [16] , whereas one study has reported low levels of FSH in males treated with VPA [13] .
Unlike the AEDs that affect the liver p450 enzyme system, LEV was not found to be associated with altered sex hormone levels in patients with epilepsy. In one study, free testosterone and androstenedione levels had been found to be elevated in patients treated with LEV compared with those in patients from the control group. However, the same elevation was also recorded in the carbamazepine and lamotrigine group. The authors have attributed these changes to the disease itself [27] . In another study, a comparison between the LEV treatment group and control group [ ( F i g . _ 1 ) T D $ F I G ] showed no significant difference in the serum levels of sex hormones [23] . It has been shown that males who receive AEDs have reduced sperm count and motility compared with controls [28] . However, there is insufficient data in the literature regarding the effects of AEDs on sperm morphology. Available studies mostly focused on CBZ and VPA. In experimental studies, it has been shown that CBZ caused structural abnormalities in Leydig cells; however, this argument has not been supported by clinical studies [29] . In another study, VPA was found to be toxic to the seminiferous tubule [30] . Furthermore, the mechanism of the reduction in sperm count and motility caused by AEDs is still unclear.
There is little data regarding sperm analysis in patients with LEV treatment in the literature. Only one study linked LEV with reduced sperm motility [23] . Also highlighted by our study results, the alteration of sperm count and morphology without effects on the sex hormone levels suggests a different, possibly peripheral, mechanism of adverse action. LEV shows its anti-epileptic effect by different and unclear mechanisms. One of these mechanisms involves the GABAergic system. Studies using in vitro models showed that LEV is associated with GABA-A receptor modification [31] . There are supportive data present in the literature that shows the GABA signaling system is also present in peripheral organs, such as the testes. GABA-A receptors were also found in the testes as well as the central nervous system [32] [33] [34] [35] [36] . Spermatogonial stem cells located in the basal membrane of the seminiferous tubules are responsible for the production of sperm. In an animal model, it has been shown that GABAergic signaling reduced the proliferation of spermatogonial stem cells [37] . However, two weaknesses should be recognized in this framework. First, the association of LEV and GABA signaling needs strong supportive arguments, and second, the association of GABA signaling and spermatogonial proliferation should be supported by further studies. Another possible explanation of peripheral interference of LEV is the SV2A receptor. SV2A is the most frequently presented form of synaptic vesicle in the glycoprotein family. These receptors were widely present in the CNS and endocrine cells [38] . SV2A is present in the composition of the synaptic vesicle membrane in presynaptic terminals. It has been shown that LEV binds to the synaptic vesicle glycoprotein, whereas other AEDs target ion channels or inhibitory neurotransmitter receptors [39] [40] [41] [42] . It is possible that the peripheral presence of such receptors in the testes could be the cause of reduced sperm parameters. However, this argument also requires further development. First of all, neither the normal function of SV2A nor the precise impact of LEV binding is well known. Furthermore, the presence or role of SV2A in the male reproductive system has not yet been discovered.
Before reaching a conclusion, one must realize that our finding in this study was consistent with a roughly 10-20% reduction in sperm parameters, which still meets infertility criteria as defined by the WHO [43] . Although our results showed a significant deterioration of seminal fluid parameters in patients with LEV treatment, the reduced fertility of epilepsy patients has a wide spectrum of etiologies in which epilepsy itself is placed in the center.
Our study has some strengths. One of them is that the pre-and post-treatment groups consisted of the same patients. We think that this will nullify various external factors. Another strength is that we assessed newly diagnosed epilepsy patients. Thus, we were able to exclude factors associated with chronicity of the disease and the effects of previously administered AEDs. The last strength is the difference in treatment durations, which enabled the assessment of treatment dose-and duration-related sperm and sex hormone abnormalities.
Our study also has some limitations. First of all, our study group is relatively small, and our findings need supportive evidence.
Furthermore, our follow-up period is relatively short, and we could only provide data on the early effects of LEV administration. Considering the chronicity of the disease, we believe that determining long-term effects of LEV treatment on the reproductive system has the utmost importance.
Conclusion
Our findings confirm that LEV treatment of newly diagnosed epilepsy patients decreases sperm parameters without altering sex hormone levels in the first few months of treatment. On the balance of supportive data, we conclude that this interaction emerges as a peripheral organ effect and needs to be investigated more thoroughly. Our results may guide the choice of antiepileptic drug treatment among men with epilepsy.
